Current Pharmacogenomics

Adrián LLerena , MD, Ph.D
Extremadura University
Hospital and Medical School
Badajoz, Extremadura
Spain

Back

Pharmacological Suppression of Premature Stop Mutations that Cause Genetic Diseases

Author(s): K. M. Keeling and D. M. Bedwell

Affiliation: Department of Microbiology, BBRB 432/Box 8, 1530 Third Avenue, South, The University of Alabama atBirmingham, Birmingham, AL 35294-2170, USA.

Abstract:

Aminoglycoside antibiotics have long been used as antibacterial agents due to their ability to inhibit bacterial translation. However, aminoglycosides also stimulate translation errors in mammalian cells. Aminoglycosides bind to a pocket formed in a domain of the ribosomal RNA (rRNA) of the small ribosomal subunit that constitutes the decoding site in both prokaryotes and eukaryotes. Normally, accurate base pairing takes place between each successive codon and its cognate aminoacyl-tRNA within this region of the ribosome. When aminoglycosides bind to the decoding site, a conformational change decreases discrimination between cognate and near-cognate tRNAs, leading to errors in the decoding process. The ability of aminoglycosides to bind to the decoding site and induce translational misreading in eukaryotic cells is less efficient than in prokaryotic cells due to subtle differences in the sequence of the decoding site rRNA. The observation that aminoglycosides induce low levels of misreading in eukaryotic cells has inspired many investigations to determine whether aminoglycosides can suppress nonsense mutations that cause human diseases. Disease models in which aminoglycosides have been shown to efficiently suppress nonsense mutations include cystic fibrosis, Duchenne muscular dystrophy, Hurler syndrome, infantile neuronal lipfuscinosis, cystinosis, x-linked nephrogenic insipidus, spinal muscular atrophy, and cancer. However, if aminoglycosides are to be used clinically for suppression therapy, their efficacy must be improved and their toxicity reduced. The co-administration of other compounds that reduce aminoglycoside toxicity or the development of new compounds that suppress stop mutations may allow the realization of suppression therapy as a clinical treatment to suppress disease-causing stop mutations.

Keywords: aminoglycosides, bacterial 70S ribosome, cognate tRNAs, Cystic fibrosis (CF), fatty acid binding protein promoter (FABP), Duchenne muscular dystrophy (DMD)

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 3
ISSUE: 4
Page: [259 - 269]
Pages: 11
DOI: 10.2174/157016005774913149
Price: $58